Codexis, Inc.

Greetings and welcome to the Codexist Report 2026 Q1 Earnings Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press Start Zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Georgia Urbans, Chief Financial Officer and Chief Business Officer. Please go ahead.

Thank you, Operator. With me today are Dr. Allison Moore, Codexys' President and Chief Executive Officer, and Britton Jimenez, Senior Vice President, Sales and Marketing. During this call, management will be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our guidance for 2026 revenue, anticipated milestones, including product launches, facility expansions, technical milestones, and public announcements related thereto, as well as our strategies and prospects for revenue growth and successful execution of current and future programs and partnerships. To the extent that the statements contained in this call are not descriptions of historical facts regarding Codexys, they are forward-looking statements reflecting the beliefs and expectations of management as of the statement date, May 7th, 2026. You should not place undue reliance on these forward-looking statements because they involve known and unknown risk uncertainties, and other factors that are, in some cases, beyond Codexys' control and that could materially affect actual results. Additional information about factors that could materially affect actual results can be found in Codexys' filings with the Securities and Exchange Commission. Codexys expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. And now I'll turn the call over to Allison.

Thank you, Georgia, and thanks everyone for joining. While it's been a short eight weeks since our last call, we've accomplished a lot at Codexis. We are pleased to report another strong quarter and are busy preparing for the TIDES conference next week, where we will present important new data on our ecosynthesis technology. Codexis generates manufacturing solutions using biocatalytic enzymes. Over the last three years, we have developed the Ecosynthesis Manufacturing Platform for the production of RNA medicine, specifically siRNA, and we are now focused on bringing this to the market. The standard approach of using solid phase organic synthesis for siRNA manufacturing is complex, solvent intensive, and challenging to scale. Currently, siRNA pipelines are expanding from rare diseases to large population indications, which will create a significant manufacturing bottleneck in the next three years. Ecosynthesis has the potential to alleviate production constraints by delivering greater scalability and higher product quality with the added benefit of dramatically improving environmental impact. Last year, we achieved a number of important milestones in platform performance and industry engagement, which generated tangible interest from our customers. In 2026, the potential impact of our platform is well understood. And across the industry, we are seeing increased interest in enzymatic production solutions. Our goal is to position Codexus as the leading manufacturing technology innovator. We are operationalizing our platform through scaling, improving process control, and by our platform's unique capability of delivering superior siRNA product. A new feature of our Ecosynthesis platform is the ability to generate siRNA with specific stereochemical control. Stereoisomers exist at both ends of most siRNA molecules and are made of the same atoms, but are arranged differently in three-dimensional space. As a reminder, drug developers have little influence over stereochemistry today, as existing chemical manufacturing methods produce random mixtures that can vary in terms of therapeutic potency and purity. Our engineered enzymes used in ecosynthesis can deliver product with specific stereoisomer configurations. These stereopure molecules confer overall improved product quality and have the potential to deliver improved potency. We continue to explore the biological impact of this control and believe it could be a tremendous asset to those customers who seek ways to improve their products. Our small molecule biocatalysis business remains an important part of Codexis. and provides support for the investments we are making in ecosynthesis. We supply uniquely designed enzymes for 13 branded commercial pharmaceutical products. This portfolio continues to grow with the recent approval of Islatravir, a part of an important new combination treatment for HIV. Codex has partnered with Merck who carried out groundbreaking process chemistry, substituting a 16-step chemical synthesis with a biocatalytic cascade. This achieved a green chemistry award in 2025. We are supplying enzymes for this commercial product and are proud to participate in this supply chain for HIV patients. We are making remarkable progress at Codexis and momentum is increasing in 2026. We are proud of the advances we are making to further enhance the utility of the EcoSynthesis platform. We look forward to showing our customers and investors additional tangible proof of value of the technology. Now to update you on our commercial activities and progress, Let me turn it over to Brittain.